Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 429Breast Neoplasms 298Neoplasms 296Colorectal Neoplasms 242Neoplasm Metastasis 197Ovarian Neoplasms 171Lung Neoplasms 150Recurrence 147Prostatic Neoplasms 146Pancreatic Neoplasms 142Multiple Myeloma 136Stomach Neoplasms 129Squamous Cell Carcinoma of Head and Neck 128Melanoma 123Leukemia, Myeloid, Acute 115Endometrial Neoplasms 115Advanced Solid Tumors 113Advanced Solid Tumor 108Carcinoma, Hepatocellular 102Triple Negative Breast Neoplasms 101Small Cell Lung Carcinoma 88Uterine Cervical Neoplasms 86Lymphoma, Non-Hodgkin 83Carcinoma, Renal Cell 72Lymphoma, Follicular 71Lymphoma 67Leukemia, Lymphocytic, Chronic, B-Cell 65Solid Tumor 64Lymphoma, Large B-Cell, Diffuse 64Hematologic Neoplasms 62

Interventions

ensartinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × Solid Advanced Tumor × Clear all
NCT07448116 2026-03-04

Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.

Betta Pharmaceuticals Co., Ltd.

Phase 1/2 Recruiting
164 enrolled

Solid Advanced Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡